2015-06-02 18:54:31 UTC

Gastroparesis, Nausea and Vomiting

Clinical Snapshots

About

This AGA Clinical Snapshot is an executive summary of Dr. Camilleri's presentation during the 2015 AGA Spring Postgraduate Course at DDW® 2015 in Washington, DC.

Clinical snapshots are free to AGA members. Please log in and "purchase" the free module to add it to your account. You will then have access to the full content of the summary on this same page whenever you are logged into the website.

Takeaways

1. Know the common causes, pathophysiology, differential diagnosis and treatment of gastroparesis.

2. Identify nuances in the clinical evaluation to reach diagnosis in patients with nausea or vomiting.

3. Recognize rumination syndrome and its diagnosis.

About the Instructors

Michael Camilleri, MD, AGAF, Mayo Clinic College of Medicine

This is only a preview. Full access is reserved for AGA members. Login or learn more about becoming a member.

Introduction

There are several gastrointestinal and extra-gastrointestinal causes of nausea and vomiting. These symptoms may result from diverse pathophysiological mechanisms including failure of gastric accommodation or impaired gastric emptying.

Definition of Gastroparesis

Gastroparesis is characterized by delayed gastric emptying in the absence of mechanical obstruction of the stomach. The cardinal symptoms include postprandial fullness (early satiety), nausea, vomiting and bloating. In one tertiary referral series, diabetes accounted for about one-third of cases of gastroparesis …

More on Gastroparesis

2018 Research Grants Open for Applications

Dec. 11, 2017

Don't lose sight of award deadlines during the busy holiday season. Read on to discover open grants from the AGA Research Foundation and when applications are due.

Grant Spotlight: AGA Pilot Awards

Nov. 8, 2017

Take your new research project idea and make it a reality with an AGA research award. Eight grants are open with a Jan. 12, 2018, deadline.

Gastroparesis Treatment: The Future is Bright

Aug. 3, 2017

New drugs are in the pipeline. AGA white paper summarizes drug development for this condition.